Valion Bio annual free cash flow
2022
2023
2024
2025
Valion Bio reported −$7.0M in free cash flow for fiscal 2025, a decrease of $1.3M from the previous fiscal year.
View full Valion Bio company overview| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$7.0M | −$1.3M | — | — |
| 2024 | 2024-12-31 | −$5.7M | $2.9M | — | −733.97% |
| 2023 | 2023-12-31 | −$8.6M | $301,000 | — | −733.76% |
| 2022 | 2022-12-31 | −$8.9M | — | — | −485.33% |
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$5.3M | −$3.5M | — | — |
| Q1 2026 | 2026-03-31 | −$5.0M | −$4.1M | — | — |
| Q4 2025 | 2025-12-31 | −$2.3M | −$538,000 | — | — |
| Q3 2025 | 2025-09-30 | −$2.0M | −$135,000 | — | −1373.97% |
| Q2 2025 | 2025-06-30 | −$1.8M | $634,000 | — | −2127.91% |
| Q1 2025 | 2025-03-31 | −$889,000 | $1.6M | — | −1270.00% |
| Q4 2023 | 2023-12-31 | −$1.8M | $453,000 | — | −496.92% |
| Q3 2023 | 2023-09-30 | −$1.9M | $906,000 | — | −663.48% |
| Q2 2023 | 2023-06-30 | −$2.5M | −$712,000 | — | −1530.43% |
| Q1 2023 | 2023-03-31 | −$2.5M | −$346,000 | — | −670.21% |
| Q4 2022 | 2022-12-31 | −$2.2M | — | — | −547.17% |
| Q3 2022 | 2022-09-30 | −$2.8M | — | — | −582.18% |
| Q2 2022 | 2022-06-30 | −$1.8M | — | — | −331.82% |
| Q1 2022 | 2022-03-31 | −$2.2M | — | — | −507.94% |
Valion Bio's latest reported quarter, Q2 2026, generated −$5.3M in free cash flow, a decrease of $3.5M year over year.
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Valion Bio filings at SEC.gov ↗